BIOMAT Database Logo BIOMAT Database Logo

Emergence of rifampin-resistant Mycobacterium tuberculosis in Massachusetts. 1976

K D Stottmeier

Tests of sensitivity to rifampin of over 2,200 strains of Mycobacterium tuberculosis demonstrated a progressive increase in the number of rifampin-resistant isolates during the past four years in Massachusetts. No resistant strains were isolated in 1971, but two strains resistant to 1 mug of rifampin/ml were isolated in 1972. Nine rifampin-resistant strains were isolated in 1973 and 16 were isolated in 1974. All but two of the resistant strains were isolated from patients who had received therapy for tuberculosis and had demonstrated resistance to other antituberculous agents. Rifampin-resistant strains were isolated from two patients, however, who had not received prior chemotherapy. Both strains were fully susceptible in vitro to other antituberculous drugs.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D008404 Massachusetts State bounded on the north by New Hampshire and Vermont, on the east by the Atlantic Ocean, on the south by Connecticut and Rhode Island, and on the west by New York.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D013307 Streptomycin An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. Estreptomicina CEPA,Estreptomicina Clariana,Estreptomicina Normon,Strepto-Fatol,Strepto-Hefa,Streptomycin Grünenthal,Streptomycin Sulfate,Streptomycin Sulfate (2:3) Salt,Streptomycin Sulphate,Streptomycine Panpharma,Strepto Fatol,Strepto Hefa

Related Publications

K D Stottmeier
Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates.
September 2007, Journal of clinical microbiology,
K D Stottmeier
Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections.
September 1970, The New England journal of medicine,
K D Stottmeier
[Detection of rifampin resistant mycobacterium tuberculosis complex using denaturing HPLC].
April 2008, The Korean journal of laboratory medicine,
K D Stottmeier
Genotyping of rifampin-resistant Mycobacterium tuberculosis isolates from western Turkey.
January 2004, Annals of Saudi medicine,
K D Stottmeier
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of M. tuberculosis to rifampin.
September 1986, The American review of respiratory disease,
K D Stottmeier
Rifampin-resistant Mycobacterium kansasii.
May 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
K D Stottmeier
Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis.
January 1997, International journal of antimicrobial agents,
K D Stottmeier
rpoB mutations as an epidemiologic marker in rifampin-resistant Mycobacterium tuberculosis.
August 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
K D Stottmeier
Emergence of rifampin-resistant Haemophilus influenzae.
March 1982, Antimicrobial agents and chemotherapy,
K D Stottmeier
Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China.
January 2013, Tuberculosis (Edinburgh, Scotland),
Copied contents to your clipboard!